ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email!
Cardiovascular Drug Delivery - technologies,markets and companies Published on September 2011
Report Summary Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems. Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology. Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described. Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents. New cell-based therapeutic strategies are being developed in response to the shortcomings of available treatments for heart disease. Potential repair by cell grafting or mobilizing endogenous cells holds particular attraction in heart disease, where the meager capacity for cardiomyocyte proliferation likely contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium. Advances in molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to treatment of these diseases. It is hoped that gene therapy will be less expensive and affordable because the techniques involved are simpler than those involved in cardiac bypass surgery, heart transplantation and stent implantation. Gene therapy would be a more physiologic approach to deliver vasoprotective molecules to the site of vascular lesion. Gene therapy is not only a sophisticated method of drug delivery; it may at time need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system. The cardiovascular drug delivery markets are estimated for the years 2010 to 2020 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 1/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Selected 96 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 75 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 27 tables and 6 figures
Table of Content TABLE OF CONTENTS 0. Executive Summary 11 1. Cardiovascular Diseases 13 Introduction 13 History of cardiovascular drug delivery 13 Overview of cardiovascular disease 14 Coronary artery disease 14 Angina pectoris 14 Limitations of current therapies for myocardial ischemic disease 14 Cardiomyopathies 14 Cardiac arrhythmias 15 Congestive heart failure 15 Peripheral arterial disease 15 Current management 16 Atherosclerosis 16 The endothelium as a target for cardiovascular therapeutics 16 Molecular cardiology 17 Cardiogenomics 17 Cardioproteomics 17 Personalized cardiology 18 Pharmacogenomics of cardiovascular disorders 18 Modifying the genetic risk for myocardial infarction 19 Management of heart failure 19 Management of hypertension 20 Pharmacogenomics of diuretic drugs 20 Pharmacogenomics of ACE inhibitors 20 Management of hypertension by personalized approach 21 Pharmacogenetics of lipid-lowering therapies 21 Polymorphisms in genes involved in cholesterol metabolism 21 Role of eNOS gene polymorphisms 22 Important advances in cardiovascular therapeutics 22 Drug delivery, biotechnology and the cardiovascular system 23 Role of cardiovascular imaging in cardiovascular therapeutics 23 Chronopharmacotherapy of cardiovascular diseases 23 2. Methods for Drug Delivery to the Cardiovascular System 25 Introduction 25 Routes of drug delivery to the cardiovascular system 25 Local administration of drugs to the cardiovascular system 25 Intramyocardial drug delivery 25
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 2/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Drug delivery via coronary venous system 26 Intrapericardial drug delivery 26 Formulations for drug delivery to the cardiovascular system 27 Sustained and controlled release 27 Programming the release at a defined time 28 Dosage formulation of calcium channel blockers 28 Sustained and controlled release verapamil 28 Methods of administration of proteins and peptides 28 Delivery of peptides by subcutaneous injection 29 Depot formulations and implants 29 Poly(ethylene glycol) technology 29 Microencapsulation for protein delivery 30 Localized delivery of biomaterials for tissue engineering 30 Oral delivery of proteins and peptides 30 DDS to improve systemic delivery of cardiovascular drugs 32 Nanotechnology-based drug delivery 32 Controlled delivery of nanoparticles to injured vasculature 33 Nanoparticles for cardiovascular imaging and targeted drug delivery 34 Nanofiber-based scaffolds with drug-release properties 34 Targeted drug delivery to the cardiovascular system 34 Immunotargeting of liposomes to activated vascular endothelial cells 35 PEGylated biodegradable particles targeted to inflamed endothelium 36 Devices for cardiovascular drug delivery 36 Local drug delivery by catheters 37 Microneedle for periarterial injection 38 Nanotechnology-based devices for the cardiovascular system 39 Liposomal nanodevices for targeted cardiovascular drug delivery 39 Nanotechnology approach to the problem of 'vulnerable plaque' 40 Drug delivery in the management of cardiovascular disease 40 Drug delivery in the management of hypertension 40 Transnasal drug delivery for hypertension 41 Transdermal drug delivery for hypertension 41 Oral extended and controlled release preparations for hypertension 42 Long-acting hypertensives for 24 h blood pressure control 43 Drug delivery to control early morning blood pressure peak 43 Role of drug delivery in improving compliance with antihypertensive therapy 44 Drug delivery for congestive heart failure 44 Oral human brain-type natriuretic peptide 44 Nitric oxide-based therapies for congestive heart failure 44 Automated drug delivery system for cardiac failure 45 DDS in the management of ischemic heart disease 45 Intravenous emulsified formulations of halogenated anesthetics 46 Injectable peptide nanofibers for myocardial ischemia 46 Delivery of angiogenesis-inducing agents for myocardial ischemia 47 Drug delivery for cardioprotection 47 Drug delivery for cardiac rhythm disorders 48 Drug delivery in the treatment of angina pectoris 49 Sustained and controlled-release nitrate for angina pectoris 49
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 3/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Transdermal nitrate therapy 49 Controlled release calcium blockers for angina pectoris 51 Vaccines for hypertension 51 Drug delivery in the management of pulmonary hypertension 51 Prostacyclin by inhalation 52 Endothelin receptor antagonist treatment of PAH 52 Anticoagulation in cardiovascular disease 52 Oral heparin 52 Low molecular weight heparin-loaded polymeric nanoparticles 53 Transdermal anticoagulants 53 Thrombolysis for cardiovascular disorders 53 Use of ultrasound to facilitate thrombolysis 54 Delivery of alteplase through the AngioJet rheolytic catheter 54 Drug delivery for peripheral arterial disease 54 Delivery of thrombolytic agent to the clot through a catheter 55 Delivery of growth factors to promote angiogenesis in ischemic limbs 55 Immune modulation therapy for PAD 55 NO-based therapies for peripheral arterial disease 55 Drug delivery in the management of hypercholesterolemia 56 Controlled/sustained release formulations of statins 56 Combinations of statins with other drugs to increase efficacy 56 Controlled release fenofibrate 57 Extended release nicotinic acid 58 Intravenous infusion of lipoprotein preparations to raise HDL 59 Innovative approaches to hypercholesterolemia 59 Single dose therapy for more than one cardiovascular disorder 59 3. Cell Therapy for Cardiovascular Disorders 61 Introduction 61 Inducing the proliferation of cardiomyocytes 61 Role of stem cells in repair of the heart 61 Cell-mediated immune modulation for chronic heart disease 61 Cell therapy for atherosclerotic coronary artery disease 62 Transplantation of myoblasts for myocardial infarction 62 MyoCell' (Bioheart) 63 Transplantation of cardiac progenitor cells for revascularization of myocardium 64 Methods of delivery of cells to the heart 64 Cellular cardiomyoplasty 64 IGF-1 delivery by nanofibers to improve cell therapy for MI 65 Intracoronary infusion of bone marrow-derived cells for AMI 65 Non-invasive delivery of cells to the heart by Morph速guide catheter 65 Transplantation of stem cells for myocardial infarction 66 Transplantation of embryonic stem cells 66 Transplantation of hematopoietic stem cells 66 Transplantation of cord blood stem cells for myocardial infarction 66 Intracoronary infusion of mobilized peripheral blood stem cells 67 Human mesenchymal stem cells for cardiac regeneration 67 Cytokine preconditioning of human fetal liver CD133+ SCs 68 Transplantation of expanded adult SCs derived from the heart 68
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 4/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Transplantation of endothelial cells 68 Transplantation of genetically modified cells 69 Transplantation of cells secreting vascular endothelial growth factor 69 Transplantation of genetically modified bone marrow stem cells 69 Cell transplantation for congestive heart failure 69 Myoblasts for treatment of congestive heart failure 69 Injection of adult stem cells for congestive heart failure 70 Role of cell therapy in cardiac arrhythmias 70 Atrioventricular conduction block 71 Ventricular tachycardia 71 ESCs for correction of congenital heart defects 72 Cardiac progenitors cells for treatment of heart disease in children 72 Stem cell therapy for peripheral arterial disease 72 Targeted delivery of endothelial progenitor cells labeled with nanoparticles 73 Clinical trials of cell therapy in cardiovascular disease 73 A critical evaluation of cell therapy for heart disease 75 Publications of clinical trials of cell therapy for CVD 75 Future directions for cell therapy of CVD 76 4. Gene Therapy for Cardiovascular Disorders 79 Introduction 79 Techniques of gene transfer to the cardiovascular system 80 Direct plasmid injection into the myocardium 80 Catheter-based systems for vector delivery 80 Ultrasound microbubbles for cardiovascular gene delivery 81 Vectors for cardiovascular gene therapy 81 Adenoviral vectors for cardiovascular diseases 81 Plasmid DNA-based delivery in cardiovascular disorders 82 Intravenous rAAV vectors for targeted delivery to the heart 82 Hypoxia-regulated gene therapy for myocardial ischemia 82 Angiogenesis and gene therapy of ischemic disorders 83 Therapeutic angiogenesis vs. vascular growth factor therapy 83 Gene painting for delivery of targeted gene therapy to the heart 84 Gene delivery to vascular endothelium 84 Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles 84 Gene delivery by vascular stents 85 Gene therapy for genetic cardiovascular disorders 85 Genetic disorders predisposing to atherosclerosis 85 Familial hypercholesterolemia 86 Apolipoprotein E deficiency 87 Hypertension 87 Genetic factors for myocardial infarction 88 Acquired cardiovascular diseases 88 Coronary artery disease with angina pectoris 88 Ad5FGF-4 88 Ischemic heart disease with myocardial infarction 89 Angiogenesis for cardiovascular disease 90 Myocardial repair with IGF-1 therapy 90 miRNA gene therapy for ischemic heart disease 91
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 5/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Congestive heart failure 91 Rationale of gene therapy in CHF 91 '-ARKct gene therapy 92 Intracoronary adenovirus-mediated gene therapy for CHF 92 AAV-mediated gene transfer for CHF 92 AngioCell gene therapy for CHF 93 nNOS gene transfer in CHF 93 Gene therapy for cardiac arrhythmias 93 Gene transfer for biological pacemakers 94 Management of arrhythmias due to myoblast transplantation 95 Genetically engineered cells as biological pacemakers 95 Gene therapy and heart transplantation 95 Gene therapy for peripheral arterial disease 96 Angiogenesis by gene therapy 96 HIF-1' gene therapy for peripheral arterial disease 96 HGF gene therapy for peripheral arterial disease 97 Ischemic neuropathy secondary to peripheral arterial disease 97 Maintaining vascular patency after surgery 97 Antisense therapy for cardiovascular disorders 98 Antisense therapy for hypertension 99 Antisense therapy for hypercholesterolemia 99 RNAi for cardiovascular disorders 100 RNAi for hypercholesterolemia 100 microRNA and the cardiovascular system 101 Role of miRNAs in angiogenesis 101 Role of miRNAs in cardiac hypertrophy and failure 101 Role of miRNAs in conduction and rhythm disorders of the heart 102 miRNA-based approach for reduction of hypercholesterolemia 102 miRNAs as therapeutic targets for cardiovascular diseases 102 Future prospects of miRNA in the cardiovascular therapeutics 103 Future prospects of gene therapy of cardiovascular disorders 103 Companies involved in gene therapy of cardiovascular disorders 104 5. Drug-Eluting Stents 105 Introduction 105 Percutaneous transluminal coronary angioplasty 105 Stents 105 Restenosis 105 Pathomechanism 106 Treatment 106 Nitric oxide-based therapies for restenosis 107 Carbon monoxide inhalation for preventing restenosis 107 Antisense approaches for prevention of restenosis after angioplasty 108 miRNA-based approach for restenosis following angioplasty 109 Gene therapy to prevent restenosis after angioplasty 109 Techniques of gene therapy for restenosis 110 NOS gene therapy for restenosis 111 Non-viral gene therapy to prevent intimal hyperplasia 111 HSV-1 gene therapy to prevent intimal hyperplasia 112
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 6/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Drug delivery devices for restenosis 112 Local drug delivery by catheter 112 Absorbable metal stents 113 Drug-eluting stents 113 Various types of DES 113 CYPHER速 sirolimus-eluting coronary stent 113 Dexamethasone-eluting stents 114 NO-generating stents 114 Paclitaxel-eluting stents 115 Sirolimus-eluting vs paclitaxel-eluting stents 115 Novel technologies for DES 116 Absorbable DES 116 Bio-absorbable low-dose DES 116 Drug-eluting stents coated with polymer surfaces 116 Endeavour DES 117 Stents for delivery of gene therapy 118 Stem cell-based stents 118 VAN 10-4 DES 119 Nanotechnology-based stents 119 Drugs encapsulated in biodegradable nanoparticles 119 Magnetic nanoparticle-coated DES 119 Magnetic nanoparticles encapsulating paclitaxel targeted to stents 120 Nanocoated DES 121 Nanopores to enhance compatibility of DES 121 The ideal DES 121 Companies developing drug-eluting stents 122 Clinical trials of drug-eluting stents 123 Measurements used in clinical trials of DES 123 TAXUS paclitaxel-eluting stents 123 XIENCE' V everolimus-eluting coronary stent 124 COSTAR II clinical trial 125 Endeavor RESOLUTE zotarolimus-eluting stent system 126 CUSTOM I clinical trial 126 NOBORI CORE Trial 126 LEADERS trial 127 Comparison of DES in clinical trials 127 Comparison of DES with competing technologies 128 DES versus coronary artery bypass graft 128 DES versus bare metal stents 128 Guidelines for DES vs BMS 131 DES vs BMS for off-label indications 131 Role of DES in cases of bare-metal in-stent restenosis 131 DES versus balloon catheter coated with paclitaxel 132 DES versus intracoronary radiation therapy for recurrent stenosis 132 Cost-effectiveness of DES 133 Safety issues of DES 133 Adverse reactions to DES 133 Endothelial vascular dysfunction due to sirolismus 134
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 7/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Risk of clotting with DES 134 Clopidogrel use and long-term outcomes of patients receiving DES 135 Prasugrel as antiplatelet agent 136 Effect of blood clot on release of drug from DES 136 Use of magnetized cell lining to prevent clotting of DES 136 Long-term safety studies of DES 137 Regulatory issues of DES 138 Future prospects for treatment of restenosis by DES 139 Future role of DES in management of cardiovascular diseases 139 Stent cost and marketing strategies 140 Improvements in stent technology 140 Bioabsorbale stent 141 DES vs drug-eluting balloons 141 6. Markets for Cardiovascular Drug Delivery 143 Introduction 143 Epidemiology of cardiovascular disease 143 Cost of care of cardiovascular disorders 144 Cardiovascular markets according to important diseases 145 Antithrombotics 145 Anticholesterol agents 145 Antihypertensive agents 146 Drugs for congestive heart failure 146 Markets for innovative technologies for cardiovascular disorders 146 Markets for cell therapy of cardiovascular disorders 146 Markets for gene therapy of cardiovascular disorders 147 Markets for drug-eluting stents 147 Major players in DES market 147 Impact of safety issues on future markets for DES 147 DES market in Asia 148 Patenting and legal issues of DES 149 The financial impact of DES on cardiovascular markets 149 Unmet needs for cardiovascular drug delivery 150 Role of DDS in developing cardiovascular markets 151 Markets for cardiovascular devices 151 Marketing of innovative cardiovascular drug delivery devices 151 Direct to consumer advertising of DES 152 Future trends in the integration of drug delivery with therapeutics 152 Future prospects of cardiovascular drug delivery 152 7. Companies involved in Cardiovascular Drug Delivery 153 Profiles of companies 153 Collaborations 256 8. References 259 List of Tables Table 1 1: Landmarks in the historical evolution of cardiovascular drug delivery 13 Table 1 2: Gene polymorphisms that alter cardiovascular response to drugs 18 Table 2 1: Routes of drug delivery used for treatment of cardiovascular disorders 25 Table 2 2: Formulations for drug delivery to the cardiovascular system 27
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 8/11
ReportLinker
Find Industry reports, Company profiles and Market Statistics
>> Get this Report Now by email! Table 2 3: Improved methods of systemic drug delivery of cardiovascular drugs 32 Table 2 4: Targeted delivery of therapeutic substances to the cardiovascular system 35 Table 2 5: Classification of devices for drug delivery to the cardiovascular system 36 Table 2 6: Various methods of delivery of therapeutic agents for hypertension 41 Table 2 7: Marketed controlled/ extended release preparation for hypertension 43 Table 2 8: Drug delivery in ischemic heart disease 45 Table 2 9: Methods of delivery of nitrate therapy in angina pectoris 49 Table 2 10: Drug delivery for peripheral arterial disorders 54 Table 3 1: Clinical trials of cell therapy in cardiovascular disease 73 Table 4 1: Cardiovascular disorders for which gene therapy is being considered. 79 Table 4 2: Catheter-based systems for vector delivery to the cardiovascular system 80 Table 4 3: Potential applications of antisense in cardiovascular disorders 98 Table 4 4: Companies involved in gene therapy of cardiovascular diseases 104 Table 5 1: Treatment of restenosis 106 Table 5 2: Devices used for drug delivery in restenosis 112 Table 5 3: Companies involved in drug-eluting stents 122 Table 6 1: Prevalence of cardiovascular disorders in major markets: US 2010-2020 144 Table 6 2: Prevalence of cardiovascular disorders in major markets: Europe 2010-2020 144 Table 6 3: Prevalence of cardiovascular disorders in major markets: Japan 2010-2020 144 Table 6 4: Values of cardiovascular DDS in major markets 2010-2020 145 Table 6 5: Markets for innovative technologies for cardiovascular disorders 2010-2020 146 Table 7 1: Top 5 companies in cardiovascular drug delivery 153 Table 7 2: Collaborations in cardiovascular drug delivery 256 List of Figures Figure 1 1: Drug delivery, biotechnology and cardiovascular diseases 23 Figure 2 1: Microneedle for periarterial injection 39 Figure 5 1: Vicious circle of vascular occlusion following angioplasty and stenting 107 Figure 5 2: Medtronic's Endeavour drug-eluting stent 117 Figure 5 3: Magnetic nanoparticle-coated stent 120 Figure 6 1: Unmet needs for cardiovascular drug delivery 150
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 9/11
Find Industry reports, Company profiles and Market Statistics
ReportLinker
>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ
Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information Please verify that the product information is correct and select the format(s) you require. Cardiovascular Drug Delivery - technologies,markets and companies
Product Formats Please select the product formats and the quantity you require.
Digital Copy--USD 2 800.00
Quantity: _____
Contact Information Please enter all the information below in BLOCK CAPITALS
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
First Name:
_____________________________ Last Name: __________________________________
Email Address:
__________________________________________________________________________
Job Title:
__________________________________________________________________________
Organization:
__________________________________________________________________________
Address:
__________________________________________________________________________
City:
__________________________________________________________________________
Postal / Zip Code:
__________________________________________________________________________
Country:
__________________________________________________________________________
Phone Number:
__________________________________________________________________________
Fax Number:
__________________________________________________________________________
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 10/11
Find Industry reports, Company profiles and Market Statistics
ReportLinker
>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card
Card Number: ______________________________________________
Expiry Date
__________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer
Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check
UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms
Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Cardiovascular Drug Delivery - technologies,markets and companies (From Issuu)
Page 11/11